The first feeding studio built on student-powered clinical discovery.

A venture studio is an institutionalized co-founder: an organization that creates or co-creates ventures by providing both the operational know-how and the capital needed to take an idea from concept to company. Unlike accelerators, which invest in existing founders and ideas, studios originate ventures themselves, taking a more active role in building the company from the ground up and maintaining meaningful equity throughout.

The data is compelling. Venture studios have demonstrated a 60% IRR, and investors are increasingly drawn to the model for reasons beyond returns alone: studios offer proactive deal creation rather than passive deal selection, pro rata rights that let investors maintain ownership as portfolio companies grow, network effects that benefit every company in the portfolio, comprehensive operational support that improves startup survival rates, and more disciplined company structures that make ventures more attractive to follow-on investors. For a deeper look at the studio model and the research behind it, we recommend following Max Pog and Matthew Burris, two of the leading voices in venture studio research and design.

De-risking happens at two levels. First, through process: every team completes clinical shadowing, structured customer discovery, competitive landscape mapping, and market sizing before any venture design begins. By the time a concept is formed, it has been validated against real clinical demand and real user populations. Second, through exit strategy: rather than forcing every venture down a single commercialization path, we match each validated framework to the channel best suited for its risk profile, capital requirements, and founding team. The result is a platform that functions simultaneously as a de-risking engine, an innovation pipeline, and a scalable venture origination machine.

A feeding studio sits at the earliest stage of the innovation pipeline. Our role is to uncover unmet needs, pressure-test the market, and prototype early-stage solutions. Once a concept is validated, we "feed" it to downstream entities that specialize in full-stack development, scale, and fundraising. Unlike traditional venture studios that build 2 to 5 startups per year internally, we can explore dozens of ideas annually while keeping operations lean and capital-efficient. The feeding model is not a fallback; it is a deliberate strategic choice that lets us stay focused on breadth, speed, and repeatability while creating reliable deal flow for partners who specialize in growth.

Campuses are overflowing with untapped innovation: capstone projects, thesis work, clinical insights, and prototypes that collect dust for lack of a clear commercialization pathway. Traditional university tech transfer rarely touches these early-stage, student-driven ideas. Students are also highly motivated, extraordinarily cost-efficient, and embedded directly in the clinical environments where needs are identified. BMTT exists to catch this layer of the ecosystem before graduation erases it, surround it with structure and validation, and shepherd it toward real-world translation.

Three core advantages: throughput and scale (we can explore dozens of ideas annually, far exceeding the output of most conventional studios); lean and student-powered operations (motivated students instead of full-time R&D staff, keeping the model nimble and capital-efficient); and validated deal flow (we de-risk early concepts, creating a reliable pipeline of investable startups for partners who specialize in commercialization and growth). By bridging underleveraged university talent with the rigor of translational science, BMTT doesn't just launch companies. We launch better companies, faster, while training the next generation of innovators in the process.